iTOL-102

A Potential Stem Cell-Derived Cure for Type 1 Diabetes

iTOL-102 is our second lead program being developed as a potential cure for Type 1 Diabetes. Using our proprietary biotin-PEG microgel platform, iTOL-100, which acts to generate localized immune tolerance, insulin producing stem cell-derived pancreatic islets will be implanted in the body. These stem cell-derived pancreatic islets are potentially capable of secreting insulin in response to sugar intake, similar to how native pancreatic islet cells behave. Additionally, the use of stem cell-derived pancreatic islets provide a potentially inexhaustible supply of insulin-producing cells.

In a pre-clinical non-human primate study of our lead program using allogenic pancreatic islet cells and iTOL-100, the implanted pancreatic islets were shown to act as native islets, secreting insulin in response to sugar intake. Additionally, study animals did not require long-term immunosuppression therapy.

Even with Insulin Treatment, There Remains a Significant Unmet Need in Type 1 Diabetes

Type 1 Diabetes is a chronic condition in which the pancreas produces little or no insulin. People with brittle diabetes frequently experience large swings in blood sugar that can quickly move from too high to too low or vice versa. Severely low blood sugar, called hypoglycemia, can cause sudden and unexpected seizures, coma, heart attacks, and even death.

70K – 100K

very severe uncontrolled
type 1 diabetes; “brittle”²